People who are at high risk may take HIV prevention medicines.
People who are at high risk may take HIV prevention medicines.Medline Plus links to health information from the National Institutes of Health and other federal government agencies.Tags: Write An Essay Of Comparison And Contrast Between Private Means Of Transport And Public TransportEssay On Secret Of Happy LifeTechnology Essay WritingImportance Of A College Education EssayEssay Argumentative ExampleCrazy College EssaysExpository Essays ExamplesOutline Eating Disorder Research Paper
Despite enormous international collaborative efforts and detailed research into neutralizing antibodies and HIV specific cellular immunity, effective immunotherapy or an efficacious vaccine are not yet available.
Major aspects of HIV infection are still not well understood, and much remains to be done to ensure affected people and communities benefit from the knowledge that has accumulated and that drives clinical and public health innovation.
Reflecting this broadened scope, HIV and AIDS wants to publish articles that deal with: 1) the pathogenesis of HIV and SIV infection and those that deal with the molecular origins of its immune activation and regulation; 2) genetics of HIV acquisition and disease; 3) HIV immunity and development of prophylactic vaccines; 4) origins and pathology of HIV associated non-AIDS diseases (for instance CVD and neuropathology) in patients on c ART and their potential for immunotherapy; 5) HIV eradication therapy; 6) behavioral, social and structural factors that affect HIV risk and prevention; 7) efficacy and effectiveness of public health and combination HIV prevention approaches; 8) successful engagement with HIV treatment and care.
HIV prevention might refer to practices done to prevent the spread of HIV/AIDS.
In the past decade, our thinking about HIV pathogenesis has significantly changed, and it is now believed that not the loss of CD4 T cells through HIV cytopathic infection, but the chronic inflammation that HIV induces, may eventually cause immune deficiency and non-AIDS diseases such as cardiovascular disease and inflammation induced artherosclerosis.
However, the virus-host interactions that differ pathologically from non-pathological HIV and SIV are still unknown.
Chronic immune activation and inflammation are considered major drivers of the disease, but it is unclear which interactions of HIV with the innate immune system via which receptors are critical.
It is suggested that inflammation is also the cause of HIV-associated non-AIDS diseases and, given that even in HAART-controlled HIV infections the risk for non-AIDS disease is high, inflammation may be a therapeutic target in HIV infection.
Increased risk of contracting HIV often correlates with infection by other diseases, particularly other sexually transmitted infections.
Medical professionals and scientists recommend treatment or prevention of other infections such as herpes, hepatitis A, hepatitis B, hepatitis C, human papillomavirus, syphilis, gonorrhea, and tuberculosis as an indirect way to prevent the spread of HIV infection.